Show simple item record

dc.contributor.authorMelvin, Aen
dc.contributor.authorFlanagan, Cen
dc.contributor.authorGaff, Len
dc.contributor.authorGratton, Ben
dc.contributor.authorGribble, Fionaen
dc.contributor.authorRoberts, Geoffreyen
dc.contributor.authorSemple, RKen
dc.contributor.authorO'Rahilly, Stephenen
dc.contributor.authorRubino, Fen
dc.contributor.authorStears, Aen
dc.contributor.authorSavage, Daviden
dc.date.accessioned2017-08-09T13:14:00Z
dc.date.available2017-08-09T13:14:00Z
dc.date.issued2017-10-01en
dc.identifier.issn0021-972X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/266122
dc.description.abstractContext: Familial partial lipodystrophy type 1 (FPLD1) is an extreme form of central adiposity, with peripheral lipodystrophy associated with severe manifestations of the metabolic syndrome, often poorly responsive to standard therapeutic approaches. Body mass index in FPLD1 varies but, in many cases, is below the level at which metabolic surgery is usually considered as a therapeutic option. Design: We detailed the metabolic response to gastric bypass surgery of three patients with FPLD1, refractory to medical therapy. Results: Roux-en-Y gastric bypass (RYGB) was associated with weight loss and substantial improvements in glycemic control and insulin sensitivity. All three patients were able to stop using insulin. Glucose tolerance testing in one patient demonstrated an increase in L-cell–derived gut hormone responses postoperatively. Conclusion: RYGB surgery substantially improved glycemic control in three patients with FPLD1, two of whom had body mass indices below 30 kg/m². RYGB should be considered in patients with partial lipodystrophy and refractory metabolic disease.
dc.description.sponsorshipThis work was supported by Wellcome Trust Grants WT106262, WT098498, WT095515, and WT107064 (to F.G., G.R., R.K.S., S.O., and D.B.S.), the Medical Research Council Metabolic Disease Unit, the National Institute for Health Research Cambridge Biomedical Research Centre, and the National Institute for Health Research Rare Disease Translational Research Collaboration.
dc.language.isoenen
dc.publisherThe Endocrine Society
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleRoux-en-Y Gastric Bypass Surgery in the management of Familial Partial 2 Lipodystrophy Type 1 (FPLD1)en
dc.typeArticle
prism.endingPage3620
prism.issueIdentifier10en
prism.publicationDate2017en
prism.publicationNameJournal of Clinical Endocrinology and Metabolismen
prism.startingPage3616
prism.volume102en
dc.identifier.doi10.17863/CAM.11968
dcterms.dateAccepted2017-07-21en
rioxxterms.versionofrecord10.1210/jc.2017-01235en
rioxxterms.versionAMen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2017-10-01en
dc.contributor.orcidGribble, Fiona [0000-0002-4232-2898]
dc.contributor.orcidO'Rahilly, Stephen [0000-0003-2199-4449]
dc.contributor.orcidSavage, David [0000-0002-7857-7032]
dc.identifier.eissn1945-7197
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idWELLCOME TRUST (107064/Z/15/Z)
pubs.funder-project-idEvelyn Trust (unknown)
pubs.funder-project-idMRC (MC_UU_12012/5)
pubs.funder-project-idWellcome Trust (095515/Z/11/Z)
pubs.funder-project-idWellcome Trust (098498/Z/12/Z)
pubs.funder-project-idMRC (MC_UU_12012/3)
cam.issuedOnline2017-07-26en


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International